Hikma Hikes Generics Guidance As It Prepares For New CEO
Also Picks Up US Injectables Assets From Akorn In The Wake Of Bankruptcy
After a tough 2022 for its generics business, Hikma is predicting big things for the division this year, raising its full-year guidance from 20% growth to nearly 30% as new CEO Riad Mishlawi prepares to take the reins from the start of September. Meanwhile, the firm has also picked up assets from Akorn following its collapse.
